Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

MLA

Steven M. Belknap, et al. “Rituximab-Associated Hepatitis B Virus (HBV) Reactivation in Lymphoproliferative Diseases: Meta-Analysis and Examination of FDA Safety Reports.” Annals of Oncology, vol. 22, May 2011, pp. 1170–80. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3ce2853de2758d05d51e8a60236be204&authtype=sso&custid=ns315887.

APA

Steven M. Belknap, Bara Fintel, S.-F. Lin, M.-Y. Lee, C.-Y. Kuo, Andrew M. Evens, Yu-Chieh Su, S.-S. Chuang, M.-S. Dai, Borko Jovanovic, B.-C. C. Chiu, Dennis W. Raisch, Yan Cheng, Daniel Ganger, & T.-Y. Chen. (2011). Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of Oncology, 22, 1170–1180.

Chicago

Steven M. Belknap, Bara Fintel, S.-F. Lin, M.-Y. Lee, C.-Y. Kuo, Andrew M. Evens, Yu-Chieh Su, et al. 2011. “Rituximab-Associated Hepatitis B Virus (HBV) Reactivation in Lymphoproliferative Diseases: Meta-Analysis and Examination of FDA Safety Reports.” Annals of Oncology 22 (May): 1170–80. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3ce2853de2758d05d51e8a60236be204&authtype=sso&custid=ns315887.